Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts

immunotherapy

24 stories tagged "immunotherapy"

Cancer

A 443,451-Cell Map Finds Pancreatic Tumors Are Crowds, Not Types

Inside one pancreatic tumor, NYU and UC San Diego researchers found as many as 11 distinct clones, which muddies the subtype label used to choose chemotherapy. The drug targets they point to next arrive with a history.

Autoimmune & Inflammation

Arthritis From Cancer Immunotherapy Comes Back With the Same T Cell Clones

Joint fluid drawn at a first flare and again at a relapse held the same expanded T cell clones, with a stronger inflammatory signature the second time. The durable immune memory these cancer drugs are sold on has a cost in the joints.

Cancer

The Number Behind GSK's Rectal Cancer Approval Is 47 Percent, Not 76

Independent reviewers confirmed a year-long complete response in 54 of 116 AZUR-1 patients. GSK's release also carried an exploratory 76 percent. For a narrow slice of rectal cancer patients, the drug may still spare them radiation and surgery.

Drugs & FDA

The FDA Fast-Tracked GSK's Rectal Cancer Drug and Left the Trial's Own Scorecard Out of Its Announcement

Independent reviewers found 47 percent of evaluable AZUR-1 patients held a complete response for a year, the trial's registered endpoint. The FDA's announcement quoted friendlier measures instead.

Cancer

To Keep Cancer-Fighting Cells Alive, a Sloan Kettering Lab Wants Them to Fight Less Hard

Memorial Sloan Kettering researchers say throttling exhausted T cells with a drug class already used against melanoma may keep them alive longer. So far the evidence comes only from lab and animal models.

Cancer

The Glioblastoma Trial No Drug Company Paid For Posted an 82% Six-Month Progression-Free Rate

Calgary oncologists bought controlled-release niacin at retail, added it to standard treatment, and cleared their own preset bar with room to spare. The trial is small, single-arm and untidy on paper, and it was paid for entirely with grant money.

Cancer

Nature Medicine Retracted the Lung Cancer Trial That Made Infusion Timing Look Like a Free Win

Its protocol was dated January 2022 but cited papers from 2024, and the editors called its survival curve smoother than a phase 3 trial should produce. A top journal published it anyway. The early-infusion claim is gone, but the body-clock question is still open.

Autoimmune & Inflammation

Novartis Halted Eight Autoimmune CAR-T Trials After Three Deaths, Then Called the Killer a "Known Risk"

Three people in Novartis's rap-cel trials died after a runaway inflammatory syndrome, and Bristol Myers froze enrollment in its rival product. Faster manufacturing is the leading suspect, and no public report yet says how many patients got the drug.

Drugs & FDA

FDA's Anktiva Approval for Papillary-Only Bladder Cancer Cites No Papillary-Only Patients

Seventeen months after refusing even to review ImmunityBio's application, the FDA expanded Anktiva's label by extrapolating from carcinoma in situ, and its announcement never mentioned the 80 papillary-only patients the company had actually studied.

Cancer

The Study Breaking Pancreatic Cancer's 'Shield' Was Co-Written by the Drug's Maker

The 'breakthrough' bought engineered mice eleven extra days, its headline human numbers come from a post-hoc subgroup, and one author is the chief scientist of the company that makes the drug.

Cancer

MD Anderson Made the Case for Radiation Cleanup After Immunotherapy. Then Its Own Trial Undercut It.

In the oligometastatic subgroup the strategy was built for, small and underpowered, the patients who added radiation trended the wrong way: median survival of 42 months against 75.8 for the drugs alone.

Cancer

Fused Into One Cell, a Neutrophil and a Macrophage Ate Tumors Two Ways

CAR-macrophage therapy keeps stalling in solid tumors: it can't get in, and it can't finish. Fuse a neutrophil onto it and, in mice, one dose shrank the tumor and kept it from coming back.

Cancer

The Executioner's Second Job: A Death Enzyme That Also Calls NK Cells to the Tumor

Caspase-3, the enzyme biology calls the executioner, turns out to carve a hidden, nucleus-bound form of interleukin-18 that summons NK cells to hunt tumors, a role the study says had gone unrecognized.

Cancer

A New Cancer 'Weapon' That Has Only Ever Slowed Tumors in Mice

Stanford's tissue-resident natural killer cells slowed melanoma and head-and-neck tumors in mice. John Sunwoo warned against reading too much into that. The coverage read plenty into it anyway.

Drugs & FDA

The FDA Twice Called This Melanoma Trial Uninterpretable. Then It Approved the Drug, at $450,000 a Course.

Federal reviewers rejected Replimune's melanoma therapy twice, faulting a single-arm trial they called not adequate and well-controlled and its results uninterpretable. No new controlled data ever answered them. After a 10-3 advisory vote, the FDA approved it anyway, at $450,000 a course.

Cancer

The Reason Immunotherapy Bounces Off Prostate Cancer: Tumors Chew Off a Genetic Tail to Blind the Immune System

Prostate tumors overproduce a protein that destroys the immune system's docking targets. A CRISPR tool that blocks the trick made checkpoint drugs work again, so far only in mice.

Cancer

In 2021, Creatine Spread Cancer in Mice. This Week, a UCLA Lab Said It Fights It.

A UCLA study found creatine energized cancer-fighting immune cells in mice and lab dishes. It was never tested in a patient, and a separate line of research says the same supplement feeds metastasis.

Cancer

Whether a T Cell Keeps Killing Cancer or Quits Is Written in How Its Genome Folds

Exhausted CD8 T cells are why checkpoint drugs and CAR-T so often stall. New maps of the 3D genome show their fate is set by how the DNA is physically folded, and by CTCF, the protein that does the folding.

Cancer

One Protein Keeps Your T Cells in the Fight. The Same Protein Feeds Autoimmune Disease.

In mice, deleting the LEF1 gene collapsed the reserve T cells that sustain the fight against chronic infection and cancer. The same deletion protected against autoimmune diabetes.

Cancer

No Gene Editing, No Catheter Into the Skull: A Pediatric Brain-Cancer T-Cell Trial Reported One Complete Response in 33 Young Patients

Children with diffuse pontine glioma rarely live past a year. A first-in-human trial infused 33 young patients with pediatric brain tumors, including DIPG, with T cells trained on three tumor proteins, no genetic engineering, and reported one complete response and three survivors still alive years l

Cancer

Twenty Years of Nothing on Brain Cancer, and the Best New Lead Is a Vitamin Nobody Can Patent

A University of Calgary trial added high-dose niacin to standard glioblastoma treatment and reported 82% of 24 patients progression-free at six months. The design is single-arm and early, but the molecule is a cheap, unpatentable vitamin.

Cancer

Fibrolamellar Carcinoma Hides Immune Cells in Scar Tissue. A Drug Approved in 2008 Pulled Them Back Out.

Fibrolamellar carcinoma mostly kills young adults, and checkpoint immunotherapy bounces off it. Researchers found the tumor herds T cells into fibrous bands, and a drug shelved for stem-cell work since 2008 freed them in patient tissue. No human trial has started.

Cancer

The "Secret Reason" Cancer Drugs Stop Working Was Published in February

A Montreal team's antibody against the SLAMF6 brake on T cells made the rounds this week as a fresh discovery. The paper went up in February, the work is in mice, and the antibody has not been given to a person.

Drugs & FDA

The $200K Pediatric Diabetes Shot Just Won a Bigger Label. The Number That Won Isn't the One Families Will Ever See.

The FDA gave Tzield an accelerated nod for kids 8 to 17 newly diagnosed with Stage 3 type 1 diabetes. The C-peptide number won. The endpoints families would actually feel did not.